:

3



. .
-
2012
1

:

,
(barcode) (
)

,
( )

:


( )
2


, ,

(
)

, /
, (
)
3




,

1.
2.
3.
4.
5.
6.

5
6




Cetavlon 15% 30

( Betadine)

!
1.

> 30 ( )
2.
7


(
)



( )

8
9


,
,

,
30 45

/ ,
450 ml 50 ml

500
ml 50 kg
, 10
10


11


12

,
barcode

7-10
(2-4 ),

;
:
( 3 ml
),
( 5 ml
)
6 ml )

13
 (barcode)

14
International Society of Blood Transfusion
ISBT Guideline 128

15
 (1)

(clip) ,

( )

,
,

16
17
 (2)
,

18
19


(1-2 )






, :

,
(core-Ag)
(35 42
), ,




20
 A

Hansaplast,


10-15min

, , ,

21
 A
:

4

!

,


22
 Guidelines
American Association of Blood Banks
(AABB)

23
 Blood Collection
Aseptic methods with sterile closed system.
Identify the donor record with the donor and all items associated with donor include:
collecting and processing institution, phlebotomist, date, time, expiration, component
type, volume, storage temperature, special requirements. FDA-approved container
must be sterile and pyrogen-free with anticoagulant type and volume noted.
Labels with an identifying system are established that identifies each donor, donor
record, specimens, collection container and all components. Attached at the time of
collection and to all future processed materials. Recheck all numbers and labels.
Record type of donation and any processing of unit.
For a standard collection bag=450 +/- 45 mL (an underbled (100-300 mL), or
overbled (>495 mL) unit is disposed). A low volume unit (300-404 mL) may be
transfused if labeled and only whole blood or red cells are transfused.
MCG processes the following components: Whole blood (stored at 1-6 Celsius within
30 minutes of collection). Whole blood or plasma to produce platelets, or
plateletpheresis is stored at 20-24 Celsius immediately with gentle agitation. If whole
blood collection time < 15 minutes with minimal trauma to activate coagulation, FFP
may be prepared, and if > 15 minutes, single donor plasma is prepared and
discarded. Whole blood is stored, and centrifuged at 1-6 Celsius into fresh frozen
plasma which is stored at minus 18 Celsius or colder within 8 hours of collection of
whole blood. Apheresis is also used to collect red cells, plasma or platelets.
Plasma appearance is noted if unusual (usual: clear golden yellow, sometimes green
tint with birth control pills, or white if lipemic). Extremely lipemic or icteric units should
not be used, labeled a single donor plasma and discarded.
At MCG, sterility must be maintained in component preparation or else discard
product. 24
 Blood Collection
Whole blood donation volume must be <10.5 ml blood/kg of body weight per
donation, including test samples.
If > 110 pounds, remove no more than 525 mL whole blood. If 100-110 pounds,
remove only 405-410 mL whole blood. If <100 pounds, accept only autologous
donors and collect proportionately less. All blood removed includes sample tubes.
The anticoagulant will be proportionally reduced for a reduced amount of blood in a
standard collection bag.
One venipuncture per unit, if more than one venipuncture then use a new container
and donor set, unless SOPs allow a method to preserve sterility. All collection
equipment must be single use and disposable.
When the appropriate amount of blood is collected, then segments and specimen
tubes are filled. Blood and components are placed on hold until serology and
infectious disease testing are complete.
Post-donation: observe donor, give post-donation instructions (remain sitting 10
minutes, drink more fluids than normal the next 4 hours, avoid alcohol & caffeine until
you eat, dont smoke for 30 minutes, if you feel dizzy lie down, if venipuncture starts
to bleed apply pressure for 5-10 minutes, remove bandage after a few hours, call
your physician if symptoms persist, resume normal activities when you feel alright, if
you develop an illness or infection in the next few days or hepatitis-positive HIV test-
AIDS in the next 12 months let collection site know, call collection site if you decide
later for any reason that your blood should not be used for donation). Document
adverse reactions or other incidents and notify donor of next acceptable donation.
Donor blood products are quarantined if in doubt to assess purity, potency and safety
with subsequent investigation, and evaluation for future donor deferral, disposition of
components, and reports to FDA. 25


26


27



() - 2003-2007 0,4% (4
1000 )

(0,05%)

40%
(34 95) ( )

600.000

28


1. (
)

2. (
)

29
 T
1.



2.




3.

()

30


.
,

, ,
,
.
,



,

31


,




-


2


( )

32

,
,



3



10-20 ,
30




33

,
/ .
,


,


,


,
.
(.. ,
)

34

1. :






2. :
,
,



24

35

,
. , ,
.
.
, ,
.

()
,
.

,

36

1.


()

2.


3.




37


, , ,

( ) (
)

( )

38

/
/ /

/ / /

/ -/ /

/ , )
/ /

)
(
, , )

39
 -

,



(, ,
)


-
-
,

40
 -

,




5-10 (/
)

41
 -

,




(10-15
, )

( ,
, 3 ,
)

42

1. : ,
,

2. :

/
(
,
)

43


,
,

,

,

44

1.
:

2.
30

3.
, ,

4.
, 45

1. ,
. :


: -
, , )
2. .
:

46
 -

, , , ,

47
 -

( /)

,

48
 -

49
 -

,
,

50


51
 ;

1914: apheresis (Abel, Rowntree,

Turner)

52
 -

1.
o 45050ml .
(pRBCs)
2. (FFP)
3. (PLTs)
1.

(RBC,

, PLT)
2.



53


: ( : ,
) ( ,
)

54


(RBC - WBC - PLT - :
)

(..

55
:

( ),

0,9% Nacl ( ),

56
57
 :

1. (priming)
:


-
2.
( - - )

3. -

HBV, HCV, HIV, HTLV, RPR

(Ht, PLT)

58


1. - -

2. ,

3.
-

59

1. 18-65
2. PLT > 140.000 / lt
3.
()

( , , -
Rh, HVB, HCV, HIV, HTLV, RPR)

60


:
PLT < 140.000 / lt
>8%

:
1.
2.
3. PLT
(1-2 )
1 ()
61

1. :



2. ( ):
2-3 h,
3. (0,9% NaCl)

:
)
)
)

62


1.

2. 15
65

, ,
)

( -
)

63


RBC

64
 1

1
:

) (Hb > 13,5 gr/dl)

)

RBC 21

42

65
 2
2 () RBC

0,9% Nacl
( : -
)


2 () RBC


66


RBC
:

) (
)

, :
2 () (prestorage)
RBC 42

67

18 - 65 :
Hb > 14 gr/dl
1,70 m
70 kgr

1. 0,9% NaCl
2. RBC
3. 6

Ht 50%

(
) 68

1.

2.

3.

4.

5. ,

6. (
)

7. ) 69


1.

2. (, )

3.

4. ()

70


1.

2.

3.

()

71

1.

2.

3.

4.

5. ()

6. ( -
) ()

72


( : - )

(
, .. ,
..

1. (.. )
2. ,

73

1. :





2.


3.


4.
( -
)
74


5.
Gravis
(.
Guillain - Barre)
Sydenham
(IgG / IgG, IgM)


6.
Wegener
. Goodpasture
( ,
HLA)
75


( ) -

RBC
(Ht ~ 80%)
RBC

:
1. ( ,
)
2.
3.
76


,
-

:
-

77


, ,

78


UVA

:

VGHD
79


( )

80


81
 ;

C
Ht (%), Hb
(mm Hg) (g/dL) (C)

A. 18 150/80 80 36% 37

B. 16 130/70 90 42% 37.7

C. 80 120/40 72 12.5 g/dL 37.5

D. 35 175/101 86 13 g/dL 36

E. 27 190/99 100 45% 36.7

82

;

E
A. 8 1

B. 48
C. 26
( 8 )
D. 35/
18
E. 17/ 37.8C

83
 :

A
. 24
B. Tattoo 7
C. 4
D. 9
E.
6

84
35
.
:
A
A.
B. 24
C. 48
D. 6
E. 12

85
 ;
E
A.

B. 10


C.
9
D.
2

E. 15

86

;
B

A. 12

B.
56
C.
f 150,000/microliter
D.
36
E.
8

87
 ;
D
A. 15
2
B. 20

24
C. 75

D. 1

1993
E. 4

, 2 , 3
1088-1995

88
 A
;

A. Hb 11 g/dL
B. H 96

C.

D. 2
7

89
90
91

AABB Technical Manual, 14th Edition, 89-145. (15th Edition
available July 2005)
American Association of Blood Banks. Donor History
Questionnaire and User Brochure; Medication Deferral List;
Donor Education Materials. www.aabb.org; May 25, 2005.
Code of Federal Regulations, revised 4-1-2003, 21, Parts 600-
799.
American Association of Blood Banks. Standards for Blood
Banks and Transfusion Services, 23rd Edition.
MCG Donor Room Manual.
MCG Donor Deferral for Community Blood Donors Manual.
FDA and CDC guidance at www.fda.gov & www.cdc.gov.
Blackall DP, Helekar PS, Triulzi DJ, Winters JL. Transfusion
Medicine Self Assessment and Review. Bethesda MD: AABB
Press, 2002; 1-16.
92